Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on CytoMed Therapeutics (NASDAQ:GDTC) and maintained a $5 price target.
October 10, 2024 | 1:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on CytoMed Therapeutics and maintained a $5 price target, indicating confidence in the stock's potential upside.
The reiteration of a Speculative Buy rating and a maintained price target of $5 by a reputable analyst suggests a positive outlook for CytoMed Therapeutics. This could lead to increased investor interest and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100